Showing 6,661 - 6,680 results of 21,342 for search '(( significantly ((greater decrease) OR (mean decrease)) ) OR ( significant decrease decrease ))', query time: 0.64s Refine Results
  1. 6661
  2. 6662
  3. 6663
  4. 6664
  5. 6665
  6. 6666
  7. 6667
  8. 6668
  9. 6669
  10. 6670
  11. 6671
  12. 6672
  13. 6673
  14. 6674
  15. 6675
  16. 6676

    Image 3_Absolute abundance calculation enhances the significance of microbiome data in antibiotic treatment studies.tif by Stefanie Wagner (743707)

    Published 2025
    “…Here, GCN correction additionally uncovered significant decreases of Lactobacillus and Faecalibacterium. …”
  17. 6677

    Image 1_Absolute abundance calculation enhances the significance of microbiome data in antibiotic treatment studies.tif by Stefanie Wagner (743707)

    Published 2025
    “…Here, GCN correction additionally uncovered significant decreases of Lactobacillus and Faecalibacterium. …”
  18. 6678

    Image 2_Absolute abundance calculation enhances the significance of microbiome data in antibiotic treatment studies.tif by Stefanie Wagner (743707)

    Published 2025
    “…Here, GCN correction additionally uncovered significant decreases of Lactobacillus and Faecalibacterium. …”
  19. 6679

    Image 4_Absolute abundance calculation enhances the significance of microbiome data in antibiotic treatment studies.tif by Stefanie Wagner (743707)

    Published 2025
    “…Here, GCN correction additionally uncovered significant decreases of Lactobacillus and Faecalibacterium. …”
  20. 6680

    Summary of study eligibility criteria. by Biban Gill (1473337)

    Published 2025
    “…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”